TD Cowen Maintains Hold on Theravance Biopharma, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Marc Frahm maintains a Hold rating on Theravance Biopharma (NASDAQ:TBPH) and lowers the price target from $10 to $9.
August 06, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TD Cowen analyst Marc Frahm maintains a Hold rating on Theravance Biopharma and lowers the price target from $10 to $9.
The lowered price target from $10 to $9 suggests a less optimistic outlook for Theravance Biopharma, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100